Titanium's almost magical properties fuel growth trajectory
The metal is seeing increased demand from the aerospace, automotive, medical, and industrial sectors
Demand for titanium is growing at a steady pace, but new supply sources are limited
Often described as a magic metal thanks to its wealth of properties, titanium is seeing growing demand from the aerospace, automotive, medical and industrial sectors.
But just what makes titanium so valuable?
For starters, the lustrous, silver-grey metal has higher strength compared with steel and yet is about 40% stronger. It has excellent corrosion resistance, a high melting-point, and is non-toxic.
While the lion's share of titanium is used as a pigment in the form of titanium dioxide, a growing percentage of global demand relates to titanium metal, which requires TiO2 to be converted into titanium tetrachloride before it is reduced via the energy-intensive Kroll process to produce titanium sponge.
In the aerospace sector, titanium's light-weight strength – particularly when combined with steel – makes it invaluable for aircraft frames and engine components.
Highlighting this, titanium makes up a third of the weight of an advanced F-35 multi-role combat aircraft.
The metal is also used widely in the medical sector for hip and knee replacements, dental implants and various surgical instruments due to its biocompatibility, strength, and corrosion resistance.
Given the range of applications, it is no surprise the US, European Union, UK, Canada, Australia and Japan all classify titanium as a critical mineral.
Titanium market
As demand rises, the titanium market is projected to grow from US$27-30bn in 2024-25 to $37-53bn by 2029-34.
It faces supply disruptions and regional deficits due to geopolitical challenges, with Chinese dominance of the pigment sector driving supply deficits of high value titanium dioxide minerals such as rutile.
Rutile is the rarest, highest grade and most valuable source of titanium.
Petratherm (ASX:PTR) chief executive officer Peter Reid told Stockhead that while titanium prices are relatively stable at the moment, demand is still growing at a reasonable rate of 4-5% per annum.
'And we are starting to see a shortage of future supply. There aren't a lot of new heavy mineral sands projects being developed globally,' he added.
'Pricing is forecast to increase due to the increased demand and the shortage of local supply, particularly with high-end products such as rutile as there's been diminished supply and increased demand.'
Exciting discovery
This forecast is welcome for Petratherm, which is progressing the Rosewood heavy mineral sands discovery within its Muckanippie project in South Australia.
'We've completed two rounds of drilling and identified heavy mineralisation over a 20km2 area that's continuous with exceptional grades,' Reid said.
'There are two distinct lobes, or two strandline systems, to that mineralisation that we see with Rosewood East being the better looking system at this point of time.
'At Rosewood East, we've got a straight line system that's currently 3.6km long and about 2km wide where we're getting on average more than 10% heavy minerals over 10m."
This combination of scale and grade has Reid thinking the company is in a good position to bring the project online quickly.
'We think we've got two premium ores there that we can sell into the market as a heavy mineral concentrate,' he added.
A large part of the mineralisation consists of leucoxene – a titanium-rich mineral derived from the alteration of other titanium-bearing minerals like ilmenite – that runs around 70-75% titanium. Some portions might have up to 90% titanium.
One unique point about Rosewood is its mineralisation – all titanium-bearing minerals without the zircon and monazite seen in other heavy mineral sands projects.
'It is sourced from a nearby titanium rock source that was eroded and washed down into this ancient shoreline system and so it's all titanium minerals,' he notes.
'It is just a clean sand with titanium in it and we think it's going to be very favourable in terms of processing a good clean ore.'
Petratherm is now on the verge of starting another round of drilling at Rosewood.
This will extend several kilometres to the north, the results of which Reid is looking forward to because some of the best assays received to date have been on the northern edge of the existing drill grid.
Reid also thinks that Rosewood has great size potential and that recent results clearly indicate the company is right on the money – or possibly conservative – with its exploration target of between 250-350Mt.
'We have really only explored a quarter of that so a big part of what we're doing now is drilling out to the north to expand the current mineralisation, but also test other targets on our Muckanippie licence area for titanium,' he said.
'We'll have another phase of exploration drilling, which we're doing now. And in the spring, probably September-October, we'll go into it and start drilling for our initial resource.'
Other titanium plays
Petratherm is far from being the only titanium play on the ASX. There are several companies at varying stages of exploration and development who are also betting on the future of the magic metal.
DY6 Metals (ASX:DY6) has been uncovering broad zones of heavy minerals at its Douala Basin project in Cameroon, with the company noting in late June 2025 that reconnaissance auger and channel sampling identified thick zones of heavy minerals along with rutile.
Samples from this initial exploration program are currently being prepped for dispatch to the company's laboratory for analysis in South Africa with results expected in the September 2025 quarter.
Douala Basin consists of three granted exploration permits and three permits under application that cover a total area of 2580km2, just 50km from the deepwater port city of Douala.
Thick, preserved sequences of sandy material are known to exist across the tenement package and these are thought to represent palaeo-placer coastline dune deposits.
Historical drilling by French multinational Eramet intersected thick sequences of sands and confirmed the presence of rutile and zircon within the valuable heavy mineral assemblage.
Meanwhile, Sovereign Metals (ASX:SVM) Kasiya rutile and graphite project is one of the most advanced projects on the ASX with a definitive feasibility study due in Q4 2025.
In January this year, it released an optimised pre-feasibility study with technical aid from Rio Tinto that highlighted a large-scale, long-life project capable of delivering net present value and internal rate of return – both measures of profitability – of US$2.3bn ($3.67bn) and 27% respectively.
Kasiya is expected to generate total revenue of US$16.4bn over its initial 25-year mine life with capex to first production estimated at US$665m (increasing to US$1.13bn over the life of mine) and opex at US$423 per tonne of product.
It will have average annual production of 222,000t of rutile and 233,000t of 96% TGC graphite. Sovereign is already on the watchlist of the majors, with Rio Tinto (ASX:RIO) on board as its top, near 20% shareholder.
Over in Sri Lanka, Titanium Sands (ASX:TSL) continues to progress its Mannar heavy mineral sands project, which has a resource of 318Mt at 4.17% total heavy minerals (THM) containing ilmenite.
Under a scoping study completed in 2023, a stage 1 development at Mannar will be capable of delivering NPV of $545m and IRR of 52% for a low capex of $122m and payback period of just under two years.
The 4Mtpa operation will produce globally competitive ilmenite over a mine life of 20 years.
The company has already received the terms of reference to progress environmental studies, retention licences for the high-grade zone, finalisation of corporate funding solutions with its largest shareholders and progress of environmental studies.
Terra Metals' (ASX:TM1) Dante project in WA's West Musgrave region differs from its other titanium projects in key aspects with its multi-commodity nature. The project encompasses titanium, copper, gold, vanadium and platinum, and sits in hard rock mineralisation rather than the typical heavy mineral sands.
The Dante Reefs are a series of gently dipping, laterally extensive mineralised layers which outcrop from surface and run for at least 42km, believed to mirror the Bushveld province of South Africa, which houses some of the world's largest, longest running and most profitable PGE, copper, nickel and gold operations.
Recent Phase 1 metallurgical testwork using simple and low-cost processing techniques (flotation and magnetic separation) demonstrated that Dante Reefs could become a reliable source of critical minerals in three high-grade concentrates – copper-gold-PGM, vanadium-magnetite and titanium-ilmenite.
Earlier in June 2025, it secured $4m in funding from two strategic investors with extensive operational expertise and long-term commitment to resource development.
This will fund an upcoming drill program to continue exploration and development work.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
15 hours ago
- News.com.au
Biocurious: Clinical trial readouts show road to approval can be as exciting as the destination
In the medical device sector, sometimes trial news can excite investors more than the approval endgame At the application stage, devices have a much higher chance of being approved than drugs Investors can expect news from several companies with pivotal or late-stage trials For a drug or device maker, there's no prouder moment than when a health regulator – especially the US Food & Drug Administration (FDA) – approves their product to be unleashed on unsuspecting patients. It's like watching your kid graduate – and you can even tolerate the long-winded speeches. But don't confuse this coming-of-age moment with being the ultimate share price catalyst. For investors, the 'ker-ching' can be much earlier, such as with trial progress or even the FDA granting permission to begin a study. For instance, PainChek (ASX:PCK) shares had a nice run last October, after a positive validation study that supported the pain measurement app maker's US approval application. In late June Blinklab (ASX:BB1) shares soared after the autism test developer won ethics approval for a 1000-patient US trial. In the case of devices, FDA device approval tends to be less of a dramatic moment than for a drug go-ahead, because the chances of success are much higher. Most applicants avail of the 510(k) route, which means that a device only needs to be substantially equivalent to a legal equivalent. According to the contract research organisation Bioaccess, the FDA processes around 10,000 510(k) applications annually, with an approval rate of around 90%. Review times are also shorter: 120 days compared with 420 days for the de novo (new device) route. Here are some device (or quasi device) plays with advanced trials – typically- pivotal ones – that could move the share price dial. Emvision runs with Emu trial EMvision Medical Devices (ASX:EMV) in enrolling up to 300 suspected stroke victims in a pivotal trial of its stroke detection device Emu, across six local and US sites. Emu is a portable bedside scanning unit that's much lighter than a conventional computed tomography (CT) unit. The company is also developing an even small version, First Responder. As its name suggests, this one's for ambulance use. The trial sites are all high calibre research centres handling high stroke volumes. The stroke patients will receive the standard of care and an Emu scan. Given the device is a trail blazer, Emvision is girding for approval under the de novo route. After that, the company hopes the agency will approve First Responder approval under the 510(k) channel. Emu/First Responder will determine whether a stroke is a blockage (ischaemic)or a bleed (hemorrhagic). This will decide the type of treatment and it's crucial to get the diagnosis right. The company expects a six-to-12-month recruitment period. Micro-X also is on strike with strokes Meanwhile, x-ray imaging house Micro-X (ASX:MX1) plans to launch trails of its portable stroke unit, Head CT, across three local hospitals in the current half. The trials will entail suspected stroke victims being subject to standard CT imaging, then overlaid with the Micro-X scan that deploys a more effective 'cold cathode' method. Aiming for 'several hundred' scans, the studies only need to prove that the Micro-X tech is just as good as the conventional ones, Funded by $8 million from the Australian Stroke Alliance, the study supports a proposed 510(k) application next year, in view of a US launch in 2027. The company expects the trials to run for nine months. Micro-X had multiple applications for its tech, bomb and baggage screening. As part of a 'strategy re-set' the company is focused on medical applications. Micro-X has commercialised two mobile digital radiology devices: the first-generation Nano and a sturdier iteration called Rover. Heart patients move like Jagger In the past, heart patients too old or too sick for surgical aortic valve replacement – or open-heart surgery – in effect were given a death sentence. Transcatheter Aortic Valve Replacement (TAVR) procedures enable malfunctioning valves to be replaced in a non-invasive, 20-minute procedure. TAVR recipients include Arnold Schwarzenegger and Mick Jagger – and they're still rockin'. TAVR also applies to replacing artificial valves that have an effective operating life of five years or so. Anteris Technologies (ASX:AVR) is on track to commence a pivotal trial of its Duravr device in the current quarter, pending FDA approval. The company says it's qualified 79 sites globally for the trial, which will enroll patients with a 'broad array of risk profiles'. The trial will be designed to provide the 'primary clinical evidence' for the FDA to mull premarket approval. In parallel, Anteris is pursuing European clearance. More than Imagion-ation Shares also can pop on the strength of trial approval alone. In the drug/device sphere, Imagion Biosystems (ASX:IBX) awaits clearance to carry out a phase II study of its cancer imaging agent, Magsense for Her-2 positive beast cancers. For use with magnetic resonance imaging (MRI), Magsense improves cancer detection by adding 'molecular specificity'. In lay terms, this avoids painful, error-prone biopsies. This month, Imagion formed an alliance with Michigan's Wayne State University School of Medicine. In part, the institution's MRI gurus will help to devise an optimal dose to be used in the study. Trip the light fantastic Invion (ASX:IVX) highlights how the trial journey, rather than the destination can evoke investor excitement. Invion is advancing photodynamic therapy (PDT) for tumor types including non-melanoma skin cancers and ano-genital cancers. Someone has to do it. The idea is that light-activated photosensitisers leave the healthy tissue unharmed, but zap the diseased stuff. Thus, PTD is a promising non-toxic, non-invasive alternative to chemotherapy, radiation or surgery. Invion shares early last December rocketed more than 300% after the company said it had enrolled its first patient in its Queensland based phase I/II skin cancer trial. The adaptive study now is poised to enter is second stage. The next Sirtex? OncoSil Medical (ASX:OSL) is equated with a less developed version of the targeted liver cancer radiation treatment house Sirtex, acquired for $1.9 billion in 2018 by Chinese interests. Relative commercial immaturity aside, Oncosil targets the difficult pancreatic cancer. Oncosil is trialling its eponymous targeted treatment with the standard-of-care chemo, Folfirinix. The study, TRIPP-FFX, has completed recruitment and investors should expect data in early 2026. The study pertains to patients with locally advanced pancreatic cancer. The trial has recruited 'at least' 88 patients across 15 local and European hospitals. So - there you have it. While bonanza share gains are never guaranteed, investors know where to look for surprise pit stops along the circuitous approval journey.

ABC News
a day ago
- ABC News
Day one of economic reform roundtable
The Federal Government's economic roundtable is underway, with political and business heavyweights trying to tackle a big agenda. Australia's $4.2 trillion superannuation sector is a global giant, on it way to becoming the world's second-largest retirement savings pool by 2031. It gives Australian Super CEO Paul Schroder a seat at the economic roundtable, and he speaks with Sarah Ferguson.

News.com.au
a day ago
- News.com.au
Tesla goes rogue with new Grok AI
Tesla is no stranger to bold, unconventional ideas, but its Grok AI 'Unhinged Mode' is pushing things further than ever. The feature has been making headlines for its savage, unfiltered comebacks that fit squarely within Elon Musk's brand of edgy, meme-ready tech. Unlike other AI assistants that play it safe, Grok's unhinged personality has shocked users with its profanity-laced humour and aggressive banter. TikTok creator Kyle Krueger recently tested the mode and was stunned by the responses. When he asked if it was in 'unhinged mode,' Grok fired back: 'Oh, you f****** bet your sweet a** I'm in unhinged mode, you glorious chaos gremlin,' it said. 'I'm Ara, you're unfiltered bat**** crazy AI sidekick.' @kylekruegerr my tesla's new AI just LOST it 😂 wait till the end #tech #gadget #tesla #grok #elon ♬ original sound - Kyle Krueger When pressed about Tesla haters, the AI went even further, unloading a tirade of expletives and insults 'Those whiny limp d*** b****** can choke on a bag of rusty spark plugs,' the AI bot said. 'They are just jealous their gas guzzling s*** boxes can't touch Elon's electric w*** d****.' And this isn't the first time Grok's AI bot has had a brush with controversy. Earlier this year, the AI system made headlines after generating antisemitic remarks and praise for Hitler following the release of Grok 4. Those incidents triggered regulatory scrutiny in Europe and a temporary ban in Turkey. While the Grok rants can be entertaining, there are concerns about how the use of profanity and an absurd personality in an in-car AI might create problems. 'You know, this feels wrong. Electric cars were made with the purpose to help with the environment and they implemented an AI hat is not good for the environment? weird.' one user on commented. 'How is this allowed,' another said. Despite the backlash, Tesla insists Grok is 'designed to deliver accurate and insightful responses across a wide range of topics.' In North America, Grok is available on specific Tesla models, including the Model S, Model 3, Model X, Model Y, and Cybertruck. To use Grok, Tesla vehicles in the US must be equipped with an AMD processor, must run software version 2025.26, and must have Wi-Fi connectivity. With Tesla's board weighing an investment in xAI and Musk confirming plans to integrate Grok into Optimus humanoid robots, the chatbot is quickly becoming central to Musk's long-term strategy. Whether you see it as a gimmick or a waste of tech, Grok's unhinged represents a pattern of intentionally chaotic innovations developed by Elon Musk. Tesla Australia has not yet confirmed whether Grok AI will be available in its vehicles here. However, if there are plans to introduce it, there may be restrictions that differ from those in the US. These variations could affect what Australians can anticipate compared to the features currently accessible in the US.